Mentioned in VRTX annual report released earlier this week. The market likes it.
Gene editing using CRISPR technology in higher animals and plants is very new, and potentially allows fixing genetic problems at the very root. Today people are talking about an exact CRISPR procedure to repair the sickle cell anemia gene. It can delete sections of the genome with precision. And a gene engineering could refill the void with normal codes in the future.
It is amusing to think about CRISPR/Cas9 techniques as new technology because bacteria have been using the method for a billion years to fight off bacteriophage infection. About ten years ago, researchers found that the bacteria carried CRISPR [Clustered Regularly Interspaced Short Palindromic Repeats] sequence in their DNA body. It took a few more years to figure out the reason. It turned out that the repeated genetic codes contained the code of phage which had attacked the bacteria before, and when attacked again by the same phage, the code sequence would be transcribed into RNA, then chopped into small pieces, each containing phage gene codes. Then Cas9 nuclease goes into action by cleaving the bonds holding the phage DNA double strands where the chopped RNA recognizes as the phage gene. Next Cas9 shreds the phage DNA and kills the phage. So, CRISPR/Cas9 is an immune system for the bacteria.
Only less than two years ago, a few groups reported that they can cut to produce a DNA double-strand break in human or mouse embryonic cells, and some reported that they repaired the cut with another gene segment to produce a new organism. They say that the technique is simple, fast, and reliable that any graduate student in biology can master it to apply to different model systems. If so, could this system be used to treat genetic abnormalities in human? Some challenges are still remaining, but those too may be overcome in future.
but they never hold the stock for even a day. This is a scam. The company needs financing because it is losing money and loses are increasing. Target on the stock is $28.
At 26.6 B , VRTX is supposed to be worth $1 B more than TESLA at $25.5 B. VRTX 's main drug is obsolete and its new drug which offers some relief for CF patients is too expensive to use.
The reason for employee count having gone down is due to the discontinuation of Incivek. The company wisely laid off about 360 employees that were connected to that drug.
If there is a positive response to my employee comment, I may sell at Jan 16 70 put for around 5.50 It was 3 less than a month ago. This annual return is tough to turn down. Comments?
2nd post of same message - do not know what happened to 1st one. i normally look at employee count as a measure of mgt confidence in the near term furture. VRTX count is deteriorating. Normally a problem. Any reason for those with whiskers here?
Thanks, not in college anymore so this is how I have to learn. It's annoying but you won't have to tell me twice.